Skip to main content

Table 3 A review of recent studies focusing on MMR immunohistochemistry in ovarian clear cell carcinoma in chronological order

From: The frequency and clinical implication of mismatch repair protein deficiency in Chinese patients with ovarian clear cell carcinoma

Study Country dMMR Rate Sample Pattern
Bennett et al. USA 6% (6/109) Whole section slides MSH2/MSH6 (3), MLH1/PMS2 (1), MSH6 (1), PMS2 (1)
Rambau et al. Canada 2.4% (4/164) Tissue microarray MSH2/MSH6 (3), MSH6 (1)
Willis et al. USA 13% (3/23) Whole section slides MSH2/MSH6 (3)
Stewart et al. Australia 6% (2/32) Whole section slides MSH2/MSH6 (2)
Howitt et al. USA 10% (3/30) Whole section slides Not mentioned
Xiao et al. China 4% (2/50) Tissue microarray MLH1/PMS2 (1), PMS2 low (1)
Parra-Herran et al. Canada 2% (2/90) Tissue microarray MSH2/MSH6 (1), MSH6 (1)
Fraune et al. Germany 0/23 Tissue microarray /
Our study China 5.6% (6/108) Whole section slides MSH2/MSH6 (4), MLH1/PMS2 (2)
  1. Abbreviations: dMMR deficient mismatch repair